The purpose of the study is to determine whether a three‑month course of MPD can improve thinking, attention, and overall quality of life compared with a control pill, which is a placebo. The trial is designed so that neither the participants nor the investigators know who receives the active drug or the control pill, ensuring an unbiased comparison.

Participants will take study tablets daily for three months and attend regular visits where simple brain‑activity recordings (explained as tests that measure the brain’s electrical signals) and mental‑function assessments (explained as tests that evaluate memory, problem‑solving, and attention) are performed, along with questionnaires about daily living and wellbeing.

After completing an earlier trial, participants may stay in the study and keep taking the medicine each day. They will visit the clinic at regular intervals where doctors will check their health, run blood tests, and ask them to fill out several questionnaires. These include a movement assessment called MDS-UPDRS, a short thinking test known as MoCA, a severity rating questionnaire (CISI-PD), a quality‑of‑life survey (PDQ-8), an anxiety and depression screen (HAD), and a questionnaire about other symptoms (NMSQ). Any side effects or abnormal lab results will be recorded, and the safety information will be compared with data from the earlier study’s active and placebo groups.

The main goal of the study is to see if the medication is safe and how well it reaches the CNS and influences a brain chemical known as 4-hydroxy-2-nonenal. Over a period of about 12 weeks, participants will take the assigned pill daily and attend regular check‑ups. At the beginning and end of the study, a small amount of fluid surrounding the brain and spinal cord, called CSF, may be collected through a thin needle to measure the level of the drug’s breakdown product AD-835 and the amount of the brain chemical. Simple brain scans using 31P-MRS may be performed to assess the brain’s energy use, and blood samples will be analyzed with LC‑MS. Laboratory tests such as ELISA, TBARS, and measurement of MDA will be used to evaluate the brain chemical levels.

The purpose of the study is to determine the dose at which the two inhaled forms provide a similar amount of levodopa in the body. Healthy adult volunteers will receive a single dose of each product on separate occasions, with a short break between each period. Before each inhaled dose, participants will take carbidopa by mouth about one hour earlier while fasting (no food). The study will record how quickly the medicine appears in the blood and will monitor safety through basic medical checks.

To conduct this research, a substance called [11C]ORM-13070 will be used. This substance is a radiotracer, which is a special compound used to create images of how the body is functioning at a cellular level. This tracer is administered through an injection. The study also utilizes PET and MRI imaging to observe the brain. PET is a method used to visualize biological processes, while MRI is a technique that uses magnetic fields to create detailed pictures of the organs and tissues within the body.

During the study, the brain is examined to look at the locus coeruleus, an area of the brain involved in the noradrenergic system. Researchers will also observe how these brain processes relate to various functions such as memory, language, sleep, and mood. The procedure involves monitoring how the radiotracer interacts with the brain receptors to better understand the changes that occur during aging and in the presence of neurological conditions.

The study will use a special imaging technique called Magnetic Resonance Spectroscopy, also known as 31P-MRS, to measure certain brain chemicals including ATP, phosphocreatine, and inorganic phosphate in specific areas of the brain such as the putamen, substantia nigra, and motor cortex. These measurements will be taken at the beginning of the study and again after four weeks of treatment to see if there are any changes. The study will also look at changes in certain substances in the blood that are related to mitochondria function.

Participants will be randomly assigned to receive either SUL-238 or placebo, and neither the participants nor the doctors will know which treatment is being given during the study. The study is designed for people who have been recently diagnosed with early Parkinson’s Disease and have not yet received treatment for the condition. Throughout the study, the safety of the treatment will be monitored by checking for any unwanted effects, measuring laboratory values, recording vital signs, performing electrocardiogram tests, and conducting physical and neurological examinations. The treatment period will last for 28 days, with a maximum total dose of 123000 milligrams and a maximum daily dose of 4500 milligrams.

The purpose of the study is to compare IPX203 with standard immediate-release levodopa/carbidopa treatment to see if it can better improve the time when patients have good control of their movement symptoms. The medication will be given as capsules that patients take by mouth. The study will look at how well patients’ symptoms are controlled throughout the day and how long the medication’s effects last.

During the 12-week study, participants will be randomly assigned to receive either IPX203 or standard levodopa/carbidopa treatment. They will need to keep track of their symptoms in a diary and undergo regular evaluations to assess how well the treatment is working. The medication comes in different strength capsules to allow for proper dose adjustment based on individual patient needs.

The study is conducted in two stages to refine how the medication is delivered. In the first stage, doctors use an MRI, which is a medical imaging technique that uses strong magnets to create detailed pictures of the body, to monitor the delivery in real time. This helps ensure the treatment reaches the correct area. In the second stage, the process is tested using a different surgical setup to see if the delivery can be successful without constant imaging monitoring. The goal is to find the most effective and consistent way to administer the treatment into the brain.

Participants in this study will have been diagnosed with Parkinson’s Disease and will already be taking medication for their condition for at least three months. The study will look at whether prasinezumab can delay the time it takes for movement problems to get worse. Prasinezumab will be given through an intravenous infusion, which means it will be delivered directly into a vein. The study will measure various aspects of how participants move and function, including detailed assessments of motor function, which refers to how well a person can control their body movements.

During the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. This includes checking for infusion-related reactions, which are responses that can happen when medication is given through a vein. Regular health checks will be performed, including measurements of vital signs such as blood pressure and heart rate, blood tests, and assessments of overall wellbeing. The study will also track changes in the amount of Parkinson’s Disease medication that participants need to take over time, as well as how participants feel about changes in their condition.

The purpose of this study is to learn more about the long-term safety and how well AB-1005 works in people with these movement disorders. This is a follow-up study for people who are currently taking part in or have previously taken part in another study testing AB-1005. The study will track participants over many years to watch for any side effects and to see how their symptoms change over time.

During the study, participants will have regular check-ups where doctors will look for any unwanted effects of the treatment and measure how well participants can move and perform daily activities. For people with Parkinson’s Disease, the study will track their motor symptoms, how much medication they need, and will use a special brain scan called 18F-DOPA PET to see how the brain is working. For people with Multiple System Atrophy, the study will measure movement abilities and quality of life using standard rating scales. The study will continue for several years to gather information about the long-term effects of this gene therapy treatment.

The purpose of the study is to find out if BHV-8000 can slow down the worsening of symptoms in people with early Parkinson’s Disease. The study will measure this by looking at how long it takes for symptoms to get worse based on a rating scale that asks about daily activities. The study will also use a special type of brain scan called DaT-SPECT, which uses a substance called ioflupane that is injected into a vein. This scan helps doctors see the activity of certain brain cells that produce a chemical called dopamine, which is important for movement. When these cells are not working properly, it suggests the disease is progressing.

People in the study will take the study medication or placebo for up to 48 weeks. During this time, doctors will regularly check how the disease is affecting movement and daily activities using different rating scales. They will also monitor safety by checking for any unwanted effects and doing laboratory tests. The study will compare two different doses of BHV-8000 to placebo to see which dose works better and is safe for people with early Parkinson’s Disease.

The purpose of this study is to find out if IRL757 is safe and well tolerated when taken daily for 12 weeks by people with Parkinson’s Disease who have moderate to severe apathy. The study will look at whether the medication causes any unwanted effects and how the body responds to it over time. Participants will need to have a caregiver who spends time with them regularly and can come to study visits.

During the study, participants will take the assigned capsules every day for 12 weeks. The doctors will check for any side effects by doing physical examinations, blood tests, heart tests, and asking questions about mood, behavior, and sleepiness. They will also measure changes in apathy symptoms using questionnaires that ask about motivation, interest in activities, and emotional responses. Participants must continue taking their regular medications for Parkinson’s Disease at the same doses throughout the study.

The purpose of this study is to find out whether taking tadalafil every day can improve movement symptoms in people with early-stage Parkinson’s disease who have not yet needed medication for their symptoms. The study will last for two weeks, during which participants will take tadalafil daily. The maximum daily amount of the medication is 20 milligrams, and the total amount taken over the entire treatment period is 210 milligrams.

During the study, movement symptoms will be measured at the beginning and again after two weeks of taking the medication to see if there are any changes. Blood pressure and heart rate will also be checked at these times. Any side effects will be recorded, including things like headache, stomach discomfort, back pain, muscle pain, facial flushing, stuffy nose, unwanted erections, and changes in sexual desire. At the end of the two weeks, participants will be asked about their experience with the treatment and how satisfied they are with the results.

The medication being tested comes in two strengths – 50 mg and 100 mg film-coated tablets that are taken by mouth. During the study, some participants will receive safinamide while others will receive placebo tablets that look identical but contain no active medication. Neither the participants nor the doctors conducting the study will know who is receiving which treatment until the study is complete.

The study will last for 12 weeks, during which participants will take their assigned medication daily while continuing their regular Parkinson’s disease treatments. Throughout the study, doctors will measure changes in pain levels using a rating scale that helps track if the pain is getting better or worse. They will also monitor other aspects of Parkinson’s disease symptoms and how they affect daily life.

The purpose of this research is to determine if Lecigon therapy is more effective than standard medical treatment in managing certain behavioral and neuropsychiatric symptoms that can occur in Parkinson’s Disease patients. These symptoms include mood changes and behavioral complications that may develop during the course of the disease.

The study treatment involves delivering the medication directly into the intestine as a gel. Patients will receive treatment for up to 12 months, during which time their symptoms and response to the medication will be monitored. The medication is designed to provide more consistent control of Parkinson’s Disease symptoms compared to traditional oral medications.

The study compares Atomoxetine Aurobindo hard capsules (40 mg) with a placebo. The medication or placebo will be taken orally. The main purpose is to determine whether atomoxetine can reduce the amount of time patients experience freezing episodes, particularly when their regular Parkinson’s medication is wearing off.

During the study, participants will undergo various walking tests to measure how the medication affects their walking ability and freezing episodes. The research will also examine how the medication influences brain activity patterns. The medication being tested is provided in a modified package to ensure neither the patient nor the researcher knows whether they are receiving the actual medication or placebo during the study period.

The purpose of this study is to investigate changes in the brain’s serotonin system during the early stages of Parkinson’s disease. The research specifically looks at people who carry a particular genetic change in the SNCA gene, which is associated with Parkinson’s disease. The study will compare these individuals with healthy people who do not have this genetic change.

During the study, participants will receive the imaging substances through an intravenous injection. They will undergo brain scanning procedures that include MRI (Magnetic Resonance Imaging) and other specialized imaging tests. The study will examine how these substances bind to specific areas in the brain and what this reveals about the early stages of the disease.

The purpose of this study is to compare how well the new Rotigotine patch adheres to the skin compared to the currently available patch. This is important because proper adhesion ensures consistent delivery of medication. The study has a crossover design, meaning that participants will try both the test patch and the reference patch at different times during the study, allowing for direct comparison between the two products.

During the trial, participants will wear each type of patch, and researchers will assess how well the patches remain attached to the skin near the end of the wearing period (after almost 24 hours). The study will also monitor any adverse events (unwanted side effects) that might occur during the use of either patch. Participants will need to avoid activities like swimming, bathing, or using saunas on assessment days as these could affect how well the patches stick to the skin.

Participants in the study will receive the treatment through an injection into a specific area at the base of the skull, known as the cisterna magna. The study will look at two different dose levels of the treatment to see how the body responds. Researchers will monitor participants for any side effects and changes in their health. The study will also measure levels of certain substances in the blood and spinal fluid to understand how the treatment affects the body.

The trial aims to gather information over several years to ensure a thorough understanding of the treatment’s safety and effects. Participants will be closely observed throughout the study to track any changes in their condition and overall health. This research is important for developing new ways to manage Parkinson’s Disease, especially for those with specific genetic mutations like the GBA1 mutation.

Participants in the study will receive an injection of the [18F]PI-2620 solution. After the injection, they will undergo a PET scan, which is a type of imaging test that helps doctors see how the agent is distributed in the brain. This will help researchers understand the differences in brain activity between those with Progressive Supranuclear Palsy, Parkinson’s Disease, and healthy individuals. The study will also look at how these differences relate to various factors like age, clinical symptoms, and other biological markers found in the body.

The study is expected to continue until the end of 2026, with recruitment of participants starting in mid-2024. By participating in this study, researchers hope to gain valuable insights into these neurological conditions, which could lead to better understanding and potentially improved treatments in the future.

The purpose of the study is to compare the activity of the 5-HT4 receptor in patients with mild to moderate Parkinson’s disease to that in healthy individuals of similar age. Participants will receive an injection of [C11]-SB207145, which will allow researchers to observe the brain’s activity using imaging techniques. This will help in understanding how the disease affects the brain and may provide insights into new ways to treat or manage Parkinson’s disease.

Throughout the study, participants will undergo various assessments to measure the expression of the tracer, which is the substance used to highlight the 5-HT4 receptor in the brain. The study will also explore how this expression relates to different symptoms of Parkinson’s disease, such as motor and cognitive symptoms, as well as any genetic factors that might influence the disease. The study is expected to continue until 2025, providing valuable information that could contribute to future treatments for Parkinson’s disease.

Participants in the study will be randomly assigned to receive either NEU-411 or a placebo. The study will last for about 52 weeks, during which participants will take the medication in the form of a tablet. The study will monitor changes in symptoms and any side effects that may occur. The goal is to see if NEU-411 can improve the symptoms of Parkinson’s disease compared to the placebo.

The study uses a special test called the QIAseq Exome Complete System to identify participants who have the LRRK2-driven form of Parkinson’s disease. This test helps determine who is most likely to benefit from NEU-411. The study will also track changes in motor and non-motor functions using a scale called the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). This trial aims to provide valuable information about the potential benefits of NEU-411 for people with early Parkinson’s disease.

Participants in the study will be randomly assigned to receive either CVN424 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 12 weeks, during which participants will take the medication once daily. Throughout the study, participants will keep a diary to record their symptoms and any changes in their condition. The study aims to compare the changes in OFF time between those taking CVN424 and those taking the placebo.

Safety is an important part of the study, and participants will be monitored for any side effects or changes in their health. This will include regular check-ups, physical exams, and tests like ECGs, which measure heart activity. The study will also use questionnaires and scales to assess any improvements in symptoms and overall well-being. The results will help determine if CVN424 is a safe and effective treatment option for people with Parkinson’s Disease who experience motor complications.

The study will compare how well these different treatments work in patients who have difficulty with their regular Parkinson’s medication. Participants will receive either Dacepton (which contains apomorphine) as an injection under the skin, Xifaxan (which contains rifaximin) as tablets taken by mouth, or placebo capsules. Some participants will also continue taking their regular Madopar medication, which contains a combination of levodopa and benserazide.

During the study, patients will take different combinations of these medications. Domperidone tablets may be given to some participants to prevent possible side effects. The treatment period will last for several weeks, during which the effectiveness of these different approaches will be evaluated to determine which method works best for managing Parkinson’s disease symptoms in patients who have this specific problem with levodopa treatment.

The purpose of the study is to understand how Exenatide affects the brain and to see if it can help slow down the worsening of motor symptoms in people with early Parkinson’s disease. Participants in the study will receive the treatment and be monitored over a period of time to observe any changes in their condition. The study will also look at the safety of long-term use of Exenatide by evaluating any side effects that may occur.

Throughout the study, participants will have regular check-ups to assess their health and the progression of their Parkinson’s disease. These check-ups will include various assessments to measure physical activity and other health parameters. The study aims to provide valuable insights into the potential benefits of Exenatide for individuals with early Parkinson’s disease.

The purpose of the study is to evaluate how well [18F]MC225 can measure the activity of P-glycoprotein in the brain. Participants in the study will receive an injection of the substance, and then researchers will use imaging techniques to observe how it behaves in the brain. This process will help determine how the protein is functioning in individuals with the mentioned conditions.

Throughout the study, participants will undergo various imaging tests, such as PET scans, to track the uptake and movement of [18F]MC225 in the brain. These tests are non-invasive and will provide important data on cerebral blood flow and other brain functions. The study aims to gather information that could lead to better understanding and potentially improved treatments for these neurodegenerative diseases.

During the study, participants will be randomly assigned to receive either BIIB122 or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of 12 weeks, during which the safety and effects of the treatment will be closely monitored.

The main focus will be on observing any side effects and changes in specific biological markers related to Parkinson’s disease. These markers include changes in certain proteins in the blood and urine. The study aims to provide valuable information on how BIIB122 affects individuals with LRRK2-associated Parkinson’s disease, potentially leading to better treatment options in the future.

Participants in the study will receive either the cannabis extract or a placebo. The study will be conducted over a period of time, during which participants will take the treatment as an oral solution. The study aims to assess the safety and tolerability of the cannabis extract, as well as its impact on the quality of life, which will be measured using a health survey. Additionally, the study will look at how the treatment affects caregiver distress and patient-reported outcomes.

The study will also explore specific improvements in each disease group. For Alzheimer’s Disease, it will assess cognitive functions and agitation. For Amyotrophic Lateral Sclerosis, it will evaluate functional status. For Parkinson’s Disease, it will monitor the progression of symptoms. The results will help determine if the cannabis extract is a beneficial treatment option for these neurodegenerative diseases.

The purpose of this study is to evaluate how effective prasinezumab is compared to a placebo in delaying the progression of motor symptoms in people with early Parkinson’s disease. Participants in the study will receive either prasinezumab or a placebo through IV infusions. The study will monitor the time it takes for participants to experience a confirmed worsening of their motor symptoms. This will help researchers understand if prasinezumab can slow down the progression of the disease.

Throughout the study, participants will be regularly assessed to track any changes in their motor function and overall health. This includes monitoring for any side effects or adverse reactions to the treatment. The study aims to provide valuable information on the safety and effectiveness of prasinezumab for individuals with early Parkinson’s disease, potentially leading to better treatment options in the future.

The purpose of this research is to determine if Radotinib is safe and well-tolerated by people with Parkinson’s disease. The study involves patients who have been diagnosed with Parkinson’s disease within the past three years and have not yet started regular treatment for their condition. During the study, participants will receive either Radotinib capsules or placebo capsules to take by mouth.

Throughout the study, doctors will monitor participants’ health through various medical examinations. They will track changes in disease symptoms using specialized rating scales, measure the medication levels in the body, and assess overall quality of life. The study will also record how long it takes before participants need to start standard Parkinson’s disease medications.

The purpose of this study is to evaluate how Clozapine affects the immune system, specifically by looking at changes in a type of protein in the blood called IgG, which is part of the body’s defense system. Participants in the study will take Clozapine for a period of up to 12 months. During this time, researchers will monitor various health aspects, including changes in weight, the number of infections, and the use of antibiotics. They will also assess how well patients tolerate Clozapine and any side effects they may experience.

Throughout the study, participants will have regular visits where their motor skills, quality of life, mood, and cognitive abilities will be evaluated using different clinical scales. Blood tests will be conducted to measure levels of IgG and other immune-related proteins, as well as to check the levels of Clozapine in the blood. The study aims to provide a better understanding of how Clozapine impacts the immune system and overall health in people with Parkinson’s disease.

Participants in the study will be randomly assigned to receive either the amantadine capsules or a placebo. The study will last for three months, during which time participants will take the medication daily. Throughout the study, participants will be monitored to see how their motor fluctuations change over time. This will help researchers understand if amantadine is effective in managing these symptoms. The study is designed to be “double-blinded,” meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo, to ensure unbiased results.

By the end of the study, researchers aim to gather information on how well amantadine works in reducing motor fluctuations in people with advanced Parkinson’s disease. This information could be valuable in improving treatment options for those living with this condition. Participants will also be monitored for any side effects to ensure the safety of the medication. The study will provide insights into whether amantadine can be a beneficial add-on therapy for managing symptoms of advanced Parkinson’s disease.

The purpose of the study is to evaluate the safety and tolerability of Exidavnemab in patients with mild to moderate Parkinson’s Disease who are already on stable medication for their symptoms. Participants in the study will receive either the new treatment or a placebo, which is a substance with no active medication. The study will involve multiple doses of the treatment over a period of time to observe any potential side effects and how well the treatment is tolerated by the participants.

Throughout the study, participants will be monitored for any changes in their health, including vital signs like blood pressure and heart rate, as well as laboratory tests. The study aims to gather information on the best dose of Exidavnemab and how it behaves in the body. This research is important for understanding if Exidavnemab could be a safe and effective treatment option for people living with Parkinson’s Disease.

Participants in the study will be given either ambroxol or a placebo, which is a substance with no active medication. The study will last for a period of 60 weeks, during which participants will take the medication orally. Throughout the study, various assessments will be conducted to monitor the effects of the treatment. These assessments include evaluating motor skills, which are movements controlled by the brain, and checking for any side effects or adverse events that may occur.

Additional tests will be performed to gather more information about the participants’ health and the impact of the treatment. These tests include MRI scans, which use magnetic fields to create detailed images of the brain, and F-DOPA PET scans, which help visualize brain activity. Cognitive assessments, such as the Montreal Cognitive Assessment (MoCA), will also be conducted to evaluate memory and thinking skills. The study aims to provide valuable insights into the potential benefits of ambroxol for individuals with Parkinson’s disease and the GBA1-mutation.

Participants in the study will receive either a high dose or a low dose of Fasudil Hydrochloride, or a placebo. The study will monitor participants for any side effects and changes in their condition. The goal is to gather information on how the treatment impacts the symptoms and overall quality of life for those with Parkinson’s Disease. The study will also include assessments using various scales to measure changes in symptoms and quality of life.

Throughout the study, participants will be observed for any adverse effects, and their progress will be tracked using different evaluation tools. These tools include the MDS-Unified Parkinson’s Disease Rating Scale, which helps measure the severity of symptoms, and the PD Quality of Life Scale, which assesses the impact of the disease on daily living. The study will provide valuable insights into the potential benefits and risks of using Fasudil Hydrochloride as a treatment for Parkinson’s Disease.

Participants in the study will receive either prasinezumab or a placebo. The study is designed to be double-blind, which means neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The study will last for a total of 52 weeks, with an additional extension period where all participants will receive the treatment. During the study, participants will be monitored for changes in their symptoms and overall health.

Parkinson’s disease is a condition that affects movement, causing symptoms such as tremors, stiffness, and difficulty with balance and coordination. The study aims to see if prasinezumab can help improve these symptoms in people who are in the early stages of the disease. Participants will be assessed using various scales and tests to measure changes in their condition. The study will also monitor for any side effects or adverse reactions to the treatment. This research is important for understanding how prasinezumab might benefit people with early Parkinson’s disease and potentially improve their quality of life.

The purpose of the study is to determine the effect of the continuous infusion of ND0612 on the daily “ON” time, which is the period when patients experience fewer symptoms, without troublesome dyskinesia, a type of uncontrolled movement. Researchers will be recording the motor function of participants with Parkinson’s disease, who experience fluctuations in their ability to move. Motor fluctuations refer to changes in movement abilities, often alternating between periods where symptoms are well-controlled (“ON” time) and times when symptoms reappear (“OFF” time).

The trial will use a placebo in some of its tests, which is a harmless substance given to some participants to compare against those receiving the actual medication. This helps to ensure that any differences in outcomes are due to the medication itself. The study aims to compare the effectiveness and safety of the subcutaneous infusion versus the oral tablets in providing consistent symptom control for individuals with Parkinson’s disease.

The purpose of the study is to evaluate the safety and effectiveness of donepezil in improving cognitive performance over a period of 12 months. Participants in the study will be randomly assigned to receive either donepezil or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication orally in the form of a film-coated tablet. The trial will involve regular assessments to monitor cognitive abilities and overall health. These assessments will help determine if donepezil can provide cognitive benefits for those with mild cognitive impairment associated with Parkinson’s disease. The study aims to provide valuable insights into potential new treatment options for managing cognitive symptoms in Parkinson’s disease.

Participants in the study will be randomly assigned to receive either BIIB122 or the placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will take place over a period of time, during which participants will be monitored for any changes in their symptoms and any side effects they might experience.

The main goal is to see if BIIB122 can slow down the worsening of symptoms associated with Parkinson’s Disease. Researchers will use a specific scale called the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) to measure changes in symptoms. They will also track any adverse events or serious adverse events that occur during the study. The study aims to provide valuable information about the potential benefits and risks of BIIB122 for people living with Parkinson’s Disease.

The purpose of this study is to evaluate the safety of afamelanotide in people who have been diagnosed with early Parkinson’s Disease. Participants in the study will receive the treatment and be monitored for any side effects or changes in their condition. The study will also look at various markers in the blood and brain, such as levels of a protein called α-synuclein and inflammation indicators, to see how they change over time. Additionally, the study will assess changes in brain imaging and cognitive function.

The study will take place over a period of time, with participants receiving regular assessments to track their progress. The goal is to gather information on how afamelanotide affects individuals with early Parkinson’s Disease and to determine its safety and potential benefits. Participants will not be required to take any other Parkinson’s medications during the study period.